February 17, 2022
RegMed Investors’ (RMi) pre-open: damaged goods or is it time to consider near-term intentions?
February 16, 2022
RegMed Investors’ (RMi) pre-open: what’s sustainable share pricing in our universe of cell and gene therapy?
February 15, 2022
RegMed Investors’ (RMi) pre-open: a tailwind of sharply higher futures due to past headlines
February 14, 2022
RegMed Investors’ (RMi) pre-open: the new year and February have been painful, and now agonizing Q4/FY21 earnings
February 11, 2022
RegMed Investors’ (RMi) pre-open: put a cork in the cell and gene therapy bottle before trading evaporates the contents
February 10, 2022
RegMed Investors’ (RMi) pre-open: sector earnings and inflation data releases are on tap
February 9, 2022
RegMed Investors’ (RMi) pre-open: closer and closer, come sector earnings
February 8, 2022
RegMed Investors’ (RMi) pre-open: who’s up, what’s going to happen, which names and when?
February 7, 2022
RegMed Investors’ (RMi) pre-open: question of the session, what’s sustainable?
February 4, 2022
RegMed Investors’ (RMi) pre-open: picking through the fallen
February 3, 2022
RegMed Investors’ (RMi) pre-open: market’s anxiety spills over after disappointing earnings releases
February 2, 2022
RegMed Investors’ (RMi) pre-open: spinning or tilting?
February 1, 2022
RegMed Investors’ (RMi) pre-open: volatility, a liability which eats into returns or a levity enhancer
January 31, 2022
RegMed Investors’ (RMi) pre-open: wipe the slate clean, SELL into Strength after closing with strong gains Friday
January 28, 2022
RegMed Investors’ (RMi) pre-open: wrapping-up a rough week for beaten down cell and gene therapy equities
January 27, 2022
RegMed Investors’ (RMi) pre-open: The week’s volatility continued on Wednesday, but Thursday?
January 26, 2022
RegMed Investors’ (RMi) pre-open: another rock & roll trip anticipated to the upside
January 25, 2022
RegMed Investors’ (RMi) pre-open: wait, one dramatic and wild session with recovery does not make a sustainable sector
January 24, 2022
RegMed Investors’ (RMi) pre-open: sector equity and geo-politico risks are in focus as earnings’ season begins to unfold
January 21, 2022
RegMed Investors’ (RMi) pre-open: waiting for the bottom achievement after the past week’s fizzles
January 20, 2022
RegMed Investors’ (RMi) pre-open: a brutal start to the year; spreading or bending the SELL to BUY guidelines
January 19, 2022
RegMed Investors’ (RMi) pre-open: The oversold usually “pop” after steady declines
January 18, 2022
RegMed Investors’ (RMi) pre-open: one doesn’t profit from playing defense
January 14, 2022
RegMed Investors’ (RMi) pre-open: the story of the oversold, experience the pain to embrace the gain
January 13, 2022
RegMed Investors’ (RMi) pre-open: “how now brown cow”?
53 min ago
RMi Closing Bell: Tumble
9 hours 48 min ago
RMi pre-open: Ticking
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.